Breaking News in the Cannabis & Novel Medicines Industry

30 September 2021

Independent Expert Panel on MDMA and psilocybin (TGA)

Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions.

21 September 2021

Nictoine Vaping Products (TGA)

Information on legally access nicotine vaping products in Australia.

3 September 2021

Nicotine Vaping Laws are Changing (TGA)

Change to Vaping Laws in Australia mean nicotine vaping products must now be prescribed by a doctor.

26 April 2021

Global Antidepressants Market Report 2021

COVID-19 Causes a Surge in Demand for Antidepressant Drugs as Mental Health Problems Rise.

2021

Psychedelic Invest

Psychedelics are changing psychiatry and set to disrupt the alcohol, tobacco, pharmaceutical and health and wellness industries. Psychedelic Invest has said there an enormous opportunity for early investors whom are foresighted enough to look past the biased and manipulated stigma imposed on many psychedelics.

27 January 2021

How ecstasy and psilocybin are shaking up psychiatry

Regulators will soon grapple with how to safely administer powerful psychedelics for treating depression and post-traumatic stress disorder.

10 February 2020

Psychedelics move from agents of rebellion towards therapeutics

Once agents of the anti-establishment, psychedelics are now moving to the commercial market, with regulatory approvals and phase 3 trials opening the door to mainstream therapeutics.

13 February 2019

Antidepressant based on party drug gets backing from FDA advisory group

US regulatory agency could soon approve esketamine to treat depression, but questions remain about the compound's efficacy and potential for abuse.

28 April 2017

Psychedelic compound in ecstasy moves closer to approval to treat PTSD

A promising treatment that uses MDMA could help people suffering with post-traumatic stress disorder.

26 January 2017

First look at LSD in action reveals acid-trip biochemistry

Studies reveal drug's crystal structure and how it affects people's perceptions of meaning.

17 May 2016

Magic-mushroom drug lifts depression in first human trial

A hallucinogenic drug derived from magic mushrooms could be useful in treating depression, the first safety study of this approach has concluded.